Login to Your Account

Regulatory NEWS

As U.S. courts and states clear the way for drug and device companies to speak more about their products, "the FDA can't afford to sit still and silent," Peter Lurie, president of the Center for Science in the Public Interest, said Tuesday at a symposium on transparency at the agency.

In the five years since it started collecting generic drug user fees, the FDA has hired 1,000 new employees, amped up its staff training and completely reorganized the way it reviews abbreviated new drug applications (ANDAs).

HONG KONG – As it works to upgrade its biologics industry and the vaccine sector in particular, China updated the approval process for new products.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: